Eli Lilly will launch studies to investigate whether its weight loss medications can help control addictive behaviors such as smoking and alcohol and drug abuse, CEO Dave Ricks revealed in a Dec. 10 interview, Bloomberg reported.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
